Evidence map›Paper›PMID 38985303›Full record

Trial reportBlood advances2024

A phase 2 study of a longitudinal multidimensional rehabilitation program for allogeneic blood and marrow transplantation patients.

Samantha Tam, Shabbir M H Alibhai, Dima Hassanieh, Rajat Kumar, Jonas Mattsson, Eshetu G Atenafu, Lisa Avery, Lori J Bernstein, Eugene Chang, David Langelier and 2 more

Registry-linked trialAbstract readClinical Trial, Phase IIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Blood advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04966156 (A Longitudinal Multidimensional Cancer Rehab Program for Patients Undergoing Allogenic Bone and Marrow Transplantation), which is not on this map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04966156 nacompletednot on this map

A Longitudinal Multidimensional Cancer Rehab Program for Patients Undergoing Allogenic Bone and Marrow Transplantation (CaRE-4-alloBMT)

TypeinterventionalSponsorUniversity Health Network, TorontoRan2021 to 2023Enrolled80ConditionsAllogeneic Disease, Hematologic Cancer, Cancer RehabilitationArmsCaRE-4-alloBMT plus usual care group
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Samantha TamInstitute of Medical Science, University of Toronto, Toronto, ON, Canada.ORCID 0000-0002-7501-0700
Shabbir M H AlibhaiDepartment of Medicine, University Health Network, Toronto, ON, Canada.
Dima HassaniehDepartment of Supportive Care, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Rajat KumarHans Messner Allogeneic Transplant Program, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada.ORCID 0000-0002-4786-5699
Jonas MattssonHans Messner Allogeneic Transplant Program, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada.
Eshetu G AtenafuDepartment of Biostatistics, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.ORCID 0000-0002-4613-3680
Lisa AveryDepartment of Biostatistics, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.ORCID 0000-0002-8431-5143
Lori J BernsteinDepartment of Supportive Care, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.ORCID 0000-0002-2479-3223
Eugene ChangDepartment of Supportive Care, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
David LangelierDepartment of Supportive Care, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.ORCID 0000-0002-9863-5084
Paty LopezDepartment of Supportive Care, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Jennifer M JonesInstitute of Medical Science, University of Toronto, Toronto, ON, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

abstractAllogeneic blood and marrow transplantation (alloBMT) is a curative treatment for blood cancers associated with various treatment-related adverse events and morbidities for which rehabilitation programs are currently limited. A phase 2 randomized controlled trial (RCT) was conducted to assess the feasibility, acceptability, and impact of CaRE-4-alloBMT, a longitudinal, multidimensional cancer rehabilitation program for patients undergoing alloBMT. The primary outcomes included the feasibility and acceptability of the intervention and the methods. Feasibility was assessed through recruitment, retention, and adherence rates. Acceptability was assessed through qualitative interviews. Secondary clinical outcomes were collected through questionnaires and physiological assessments at 4 time points. A total of 80 participants were recruited and randomized. Recruitment (72%) and retention (70%) rates, along with qualitative findings, support the feasibility of the intervention. Adherence was suboptimal, most notably educational module completion (22.7%). Treatment effect sizes of 0.70 (95% confidence interval [CI], 0.20-1.21; 30-second sit-to-stand test) and 0.46 (95% CI, -0.17 to 1.09; 36-Item Short Form Survey) were observed in favor of the intervention. The results appear promising; however, the findings are limited by missing data owing to attrition. Modifications will be required to refine the program and inform a phase 3 RCT. This trial was registered at www.ClinicalTrials.gov as #NCT04966156.

Indexed as

Bone Marrow TransplantationTransplantation, HomologousAdultAgedFemaleHematologic NeoplasmsHumansLongitudinal StudiesMaleMiddle AgedTreatment Outcome

Identifiers

PMID38985303
PMCPMC11414680

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.